Pharmacology News and Research

Latest Pharmacology News and Research

East Asian BIM gene variant contributes to drug resistance in cancer

A multi-national research team led by scientists at Duke-NUS Graduate Medical School has identified the reason why some patients fail to respond to some of the most successful cancer drugs.

19 Mar 2012

Study reveals how Bdnf gene mutation contributes to severe obesity

Researchers at Georgetown University Medical Center have revealed how a mutation in a single gene is responsible for the inability of neurons to effectively pass along appetite suppressing signals from the body to the right place in the brain. What results is obesity caused by a voracious appetite.

19 Mar 2012

Merck announces collaboration to create Calibr for early-stage translational research

Merck, known outside the United States and Canada as MSD, today announced a collaboration to create the California Institute for Biomedical Research (Calibr), an independent, not-for-profit organization (501c3) established to accelerate the translation of basic biomedical research into innovative, new medicines to treat disease.

16 Mar 2012

Roundtable teleconference on nanotechnology against cancer

Imagine a test that sifts through millions of molecules in a drop of a patient's blood to detect a telltale protein signature of a cancer subtype, or a drug ferry that doesn't release its toxic contents until it slips inside cancer cells.

15 Mar 2012

Scientists report about a brain circuit that mediates loss of appetite

The meal is pushed way, untouched. Loss of appetite can be a fleeting queasiness or continue to the point of emaciation. While it's felt in the gut, more is going on inside the head. New findings are emerging about brain and body messaging pathways that lead to loss of appetite, and the systems in place to avoid starvation.

15 Mar 2012

HIPK2 regulator protein plays a crucial role in kidney fibrosis

Researchers from Mount Sinai School of Medicine have identified a regulator protein that plays a crucial role in kidney fibrosis, a condition that leads to kidney failure. Finding this regulator provides a new therapeutic target for the millions of Americans affected by kidney failure. The research is published in the March 11 issue of Nature Medicine.

12 Mar 2012

LSD for alcohol addiction: Study

Hallucinogenic drug LSD (lysergic acid diethylamide) could help alcoholics give up drinking, according to an analysis of studies performed in the 1960s. A study, presented in the Journal of Psychopharmacology, looked at data from six trials and more than 500 patients. It said there was a “significant beneficial effect” on alcohol abuse, which lasted several months after the drug was taken.

12 Mar 2012

Concerns about aging in good health

Do men harbour concerns about aging in good health? Do they confide these concerns to their physicians? Are men's concerns the same as women's? The answers to these questions can be found in a large cross-sectional survey of 2325 Canadian men, aged 55 to 97 years old, led by Dr. Cara Tannenbaum, Geriatrician and the Michel Saucier Endowed Chair in Geriatric Pharmacology, Health and Aging at the Institut universitaire de gériatrie de Montréal (IUGM) which is affiliated with the Université de Montréal.

10 Mar 2012

Study uncovers critical process in understanding degeneration of brain cells sensitive to AD

A research group led by Dr. A. Claudio Cuello of McGill University's Faculty of Medicine, Dept. of Pharmacology and Therapeutics, has uncovered a critical process in understanding the degeneration of brain cells sensitive to Alzheimer's disease.

9 Mar 2012

XMetA can control blood glucose levels in patients with diabetes

XOMA Corporation announced that its study of XMetA, the company's fully-human allosteric monoclonal antibody to the insulin receptor, is available online and will be published in the May issue of the American Diabetes Association's journal Diabetes.

8 Mar 2012

Heart rate lowering drug may reduce “implicit” racial prejudices: Study

It was found that volunteers given the beta-blocker, used to treat chest pains and lower heart rates, scored lower on a standard psychological test of “implicit” racist attitudes. They appeared to be less racially prejudiced at a subconscious level than another group treated with a “dummy” placebo pill.

8 Mar 2012

Symposium to cover latest breakthroughs in percutaneous treatment of CAD

The agenda for the Optimizing PCI Outcomes: A Vision for 2012 symposium is now available at: http://www.pcioutcomes.com/conference/agenda.html. This evening symposium will feature the latest clinical and experimental breakthroughs in the percutaneous treatment of coronary artery disease, including the latest clinical data on current and second-generation drug-eluting stent device-based therapies.

8 Mar 2012

CB2 receptor involved in regulating impulsive behaviour

A new study lead by the Neuroscience Institute of Alicante reveals how manipulating the endocannabinoid system can modulate high levels of impulsivity. This is the main problem in psychiatric illnesses such a schizophrenia, bipolar disorder and substance abuse.

8 Mar 2012

Loss of glutamate receptor linked to negative effects of chronic stress

Chronic stress has a more powerful effect on the brain during adolescence than in adulthood and now there's proof at the molecular level, according to findings published in Neuron by University at Buffalo researchers.

8 Mar 2012

First 'theranostic' agent for treatment of ALL

A team of researchers at Case Western Reserve University School of Medicine has developed the first "theranostic" agent for the treatment of acute lymphoblastic leukemia (ALL).

8 Mar 2012

Researchers validate CatB protease as target for Alzheimer's

Researchers at the University of California, San Diego, the Medical University of South Carolina, the University of Cincinnati, and American Life Science Pharmaceuticals of San Diego have validated the protease cathepsin B (CatB) as a target for improving memory deficits and reducing the pathology of Alzheimer's disease (AD) in an animal model representative of most AD patients.

8 Mar 2012

Transgenomic fourth quarter total revenue increases 68% to $8.6M

Transgenomic, Inc. today reported financial results for the year ended December 31, 2011 and provided a business update.

7 Mar 2012

Researchers reveal how melanoma develops resistance to Zelboraf

Cancer is tough to kill and has many ways of evading the drugs used by oncologists to try and eliminate it. Now, researchers at UCLA's Jonsson Comprehensive Cancer Center have uncovered how an advanced form of melanoma gets around an inhibitor, Zelboraf, which targets the mutated BRAF gene.

7 Mar 2012

Scientists to investigate biochemical switch: P2X1 receptor

Scientists investigating a 'biochemical switch' linked to strokes and heart disease claim to have made an advance in understanding how it is 'turned on'.

6 Mar 2012

Arrowhead, Axolabs enter into RNAi therapeutics strategic agreement

Arrowhead Research Corporation, a nanomedicine company with development programs in RNAi therapeutics and obesity, and Axolabs GmbH, a custom research organization offering preclinical solutions and consultancy in the field of oligonucleotide therapeutics, today announced that they have entered into a Strategic Alliance and Master Services Agreement.

5 Mar 2012